EDAP TMS S.A. American Depositary Shares
NASDAQ:FOCLMedical - Devices
-$0.10 today
- Market cap
- $116.19M
- Beta
- 0.00
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.82
Volume 0.16M
Average 0.04M
FOCL Net Income
Bottom-line profit after all expenses, interest, and taxes.
EDAP TMS S.A. American Depositary SharesNASDAQ: FOCL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$9.12M, compared with -$7.45M a year earlier. Trailing-twelve-month net income was -$30.77M.
Context
- Net income amounted to 41.5% of revenue in FY2025, up 11.8 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$33.96M (-15.8%) for the fiscal year ending Dec 2026, a step up from the -42.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.12M+3.5% QoQ
- Last fiscal yearDec 2025
- -$29.34M-42.6% YoY
- LTMMar 2026
- -$30.77M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -22.4% | -44.5% | -22.1 pp |
| 1 year | -42.6% | -15.8% | +26.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (29.34M) USD
- Year-over-year change
- -42.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.34M) | -42.6% |
| FY2024 | 2024-12-31 | (20.57M) | +10.2% |
| FY2023 | 2023-12-31 | (22.9M) | -642.8% |
| FY2022 | 2022-12-31 | (3.08M) | -472.6% |
| FY2021 | 2021-12-31 | 827.39K | — |
Net Income vs competitors
How FOCL compares with its peers on the latest reported figures
No competitor Net Income figures are available to compare.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 52.08M | 57.92M | 65.32M | 69.35M | 70.75M |
| Cost of Revenue | 30.31M | 32.49M | 38.93M | 40.63M | 40.65M |
| Gross Profit | 21.77M | 25.43M | 26.39M | 28.73M | 30.09M |
| Gross Margin | 41.8% | 43.9% | 40.4% | 41.4% | 42.5% |
| Research & Development | 5.62M | 6.04M | 8.21M | 9.1M | 10.13M |
| Selling, General & Admin | 19.66M | 24.73M | 40.28M | 42.58M | 45.17M |
| Operating Expenses | 25.28M | 30.77M | 48.49M | 51.68M | 55.3M |
| Depreciation & Amortization | 2.27M | 1.72M | 2.08M | 2.8M | 3.43M |
| EBITDA | 2.66M | (915.4K) | (20.31M) | (17.7M) | (25.05M) |
| EBITDA Margin | 5.1% | -1.6% | -31.1% | -25.5% | -35.4% |
| Operating Income | (3.51M) | (5.35M) | (22.1M) | (22.95M) | (25.21M) |
| Operating Margin | -6.7% | -9.2% | -33.8% | -33.1% | -35.6% |
| Interest Income | 11.82K | 424.59K | 1.42M | 861.03K | 252.78K |
| Interest Expense | 61.46K | 176.56K | 250.82K | 255.28K | 791.44K |
| Other Income / Expenses | 3.83M | 2.54M | (539.48K) | 2.2M | (4.06M) |
| Income Before Tax | 326.23K | (2.81M) | (22.64M) | (20.75M) | (29.27M) |
| Pre-Tax Margin | 0.6% | -4.9% | -34.7% | -29.9% | -41.4% |
| Income Tax Expense | (501.16K) | 269.05K | 252.73K | (183.02K) | 71.22K |
| Net Income | 827.39K | (3.08M) | (22.9M) | (20.57M) | (29.34M) |
| Net Margin | 1.6% | -5.3% | -35.0% | -29.7% | -41.5% |
| EPS (Basic) | 0.03 | (0.09) | (0.62) | (0.55) | (0.78) |
| EPS (Diluted) | 0.03 | (0.09) | (0.62) | (0.55) | (0.78) |
| Weighted Avg Shares | 32.13M | 34.39M | 37M | 37.29M | 37.44M |
| Weighted Avg Shares (Diluted) | 32.42M | 34.39M | 37M | 37.29M | 37.44M |
EDAP TMS S.A. American Depositary Shares
NASDAQ:FOCL
Intrinsic Alpha fair value
Locked
Current Price
$3.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.